Synaptic degeneration in Alzheimer’s disease

2009/04/23 by Thomas Arendt · 29 citations
Medicine · Neuroscience · #Alzheimer's disease research and treatments #Neuroscience and Neuropharmacology Research #Cholinesterase and Neurodegenerative Diseases

paper · doi:10.1007/s00401-009-0536-x

Citations

• Neuropathological stageing of Alzheimer-related changes

Cited by

• NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer’s Disease
• Comparison of [ ¹¹ C]UCB-J and [ ¹⁸ F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling study
• APOE genotype determines cell-type-specific pathological landscape of Alzheimer’s disease
• Association of APOE-ε4 and GAP-43-related presynaptic loss with β-amyloid, tau, neurodegeneration, and cognitive decline
• Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. [europepmc]
• Alzheimer disease. [europepmc]
• Reimagining Alzheimer's disease--an age-based hypothesis. [europepmc]
• Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. [europepmc]
• Dendritic spine pathology in neuropsychiatric disorders. [europepmc]
• Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus. [europepmc]
• 4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies. [europepmc]
• Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease. [europepmc]
• Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-β1-42 oligomers are revealed in vivo by using a novel animal model. [europepmc]
• A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). [europepmc]
• The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. [europepmc]
• Molecular mechanisms of cognitive dysfunction following traumatic brain injury. [europepmc]
• GSK-3β, a pivotal kinase in Alzheimer disease. [europepmc]
• Autophagy in microglia degrades extracellular β-amyloid fibrils and regulates the NLRP3 inflammasome. [europepmc]
• ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. [europepmc]
• Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease. [europepmc]
• Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies. [europepmc]
• NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer's Disease. [europepmc]
• Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases. [europepmc]
• Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases. [europepmc]
• Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment. [europepmc]
• A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain. [europepmc]
• Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. [europepmc]
• Tanshinone IIA attenuates neuroinflammation via inhibiting RAGE/NF-κB signaling pathway in vivo and in vitro. [europepmc]
• The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain. [europepmc]